Loading…
Loading…
OS (OneStream, Inc. Class A Common Stock) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lanc
AstraZeneca (AZN) is trading relatively stable after announcing two encouraging Phase III updates for lung cancer treatments, which somewhat mitigated a setback
Innovent Announces First Patient Dosed in Pivotal Registrational Study of IBI363/TAK-928 (PD-1/IL-2α-biased Bispecific Fusion Protein) in Combi
Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) demonstrated a statistically significan
Gabelli Funds LLC bought a new stake in shares of OneStream, Inc. (NASDAQ: OS) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 523,583 shares of the company's stock, valued at approximately $12,566,000. Gabelli Funds LLC owned approximately 0.21%
Annis Gardner Whiting Capital Advisors LLC increased its stake in shares of OneStream, Inc. (NASDAQ: OS) by 10.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 227,217 shares of the company's stock after acquiring an additional 20,933 shares during the
AVON, Ohio & OAKLAND, Calif.--(BUSINESS WIRE)--Advanced Polymer Coatings (APC), a global leader in polymer coatings, is making major strides in product development with chemistry AI company Albert Invent to advance and scale its modern R&D infrastructure.Through this partnership, APC is implementing Albert's AI-native operating system (OS) for chemistry and materials science to centralize experimental data, capture institutional knowledge, and enable more efficient collaboration across resea.
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited